In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aptose Biosciences Inc.

aptose.com

Latest From Aptose Biosciences Inc.

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.

Financing StartUps and SMEs

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

CrystalGenomics Raises Hefty Funds, Gears Up For New Growth In Innovation

Amid increasing exports of new drug Acelex and multiple out-licensing agreements for its investigative oncology drugs, the South Korean biotech is raising sizable new funds via stocks and bonds this year to seek new longer term growth engines by bringing in new drug assets, or seeking M&As and alliances, and speeding up progress of its R&D pipeline in global markets.

South Korea Financing

Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar

Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.

Asia Pacific Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Imutec Corp.
  • Lorus Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Aptose Biosciences Inc.
  • Senior Management
  • William G Rice, PhD, Chmn., Pres. & CEO
    Gregory K Chow, SVP, CFO
    Stephen Howell, MD, Acting CMO
    Jotin Marango, MD, PhD, SVP, CBO
  • Contact Info
  • Aptose Biosciences Inc.
    Phone: (647) 479-9828
    251 Consumers Rd.
    Ste. 1105
    Toronto, M2J 4R3
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register